More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to…
eTurboNews ບົດຄວາມແມ່ນສໍາລັບຜູ້ຈອງເທົ່ານັ້ນ. ການສະໝັກໃຊ້ແມ່ນ ອອນໄລນ໌.
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.
- ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting.
- Lebrikizumab, an investigational IL-13 inhibitor, also led to….
